252 related articles for article (PubMed ID: 34795003)
1. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer.
Sprooten J; Vankerckhoven A; Vanmeerbeek I; Borras DM; Berckmans Y; Wouters R; Laureano RS; Baert T; Boon L; Landolfo C; Testa AC; Fischerova D; Van Holsbeke C; Bourne T; Chiappa V; Froyman W; Schols D; Agostinis P; Timmerman D; Tejpar S; Vergote I; Coosemans A; Garg AD
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795003
[TBL] [Abstract][Full Text] [Related]
2. A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology.
Sprooten J; Coosemans A; Garg AD
Oncoimmunology; 2022; 11(1):2024692. PubMed ID: 35036075
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
4. A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients.
Battaglia A; Fossati M; Buzzonetti A; Scambia G; Fattorossi A
Immunol Lett; 2017 Nov; 191():35-39. PubMed ID: 28919454
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
Yan S; Fang J; Chen Y; Xie Y; Zhang S; Zhu X; Fang F
BMC Cancer; 2020 Dec; 20(1):1205. PubMed ID: 33287740
[TBL] [Abstract][Full Text] [Related]
6. Suppressive stroma-immune prognostic signature impedes immunotherapy in ovarian cancer and can be reversed by PDGFRB inhibitors.
Yang D; Duan MH; Yuan QE; Li ZL; Luo CH; Cui LY; Li LC; Xiao Y; Zhu XY; Zhang HL; Feng GK; Liu GC; Deng R; Li JD; Zhu XF
J Transl Med; 2023 Sep; 21(1):586. PubMed ID: 37658364
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.
Sun D; Zhao X; Yu Y; Li W; Gu P; Zhi Z; Xu D
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35137909
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
[TBL] [Abstract][Full Text] [Related]
10. Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.
Battaglia A; Buzzonetti A; Fossati M; Scambia G; Fattorossi A; Madiyalakan MR; Mahnke YD; Nicodemus C
Cancer Immunol Immunother; 2020 Mar; 69(3):383-397. PubMed ID: 31897661
[TBL] [Abstract][Full Text] [Related]
11. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
12. Signal Integration of IFN-I and IFN-II With TLR4 Involves Sequential Recruitment of STAT1-Complexes and NFκB to Enhance Pro-inflammatory Transcription.
Piaszyk-Borychowska A; Széles L; Csermely A; Chiang HC; Wesoły J; Lee CK; Nagy L; Bluyssen HAR
Front Immunol; 2019; 10():1253. PubMed ID: 31231385
[TBL] [Abstract][Full Text] [Related]
13. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
[TBL] [Abstract][Full Text] [Related]
14. Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment.
Theodoraki MN; Yerneni S; Sarkar SN; Orr B; Muthuswamy R; Voyten J; Modugno F; Jiang W; Grimm M; Basse PH; Bartlett DL; Edwards RP; Kalinski P
Cancer Res; 2018 Aug; 78(15):4292-4302. PubMed ID: 29853604
[TBL] [Abstract][Full Text] [Related]
15. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract][Full Text] [Related]
16. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
17. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
[TBL] [Abstract][Full Text] [Related]
18. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of prexasertib monotherapy in recurrent
Lampert EJ; Cimino-Mathews A; Lee JS; Nair J; Lee MJ; Yuno A; An D; Trepel JB; Ruppin E; Lee JM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32709712
[TBL] [Abstract][Full Text] [Related]
20. Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome.
Weiss E; Rautou PE; Fasseu M; Giabicani M; de Chambrun M; Wan J; Minsart C; Gustot T; Couvineau A; Maiwall R; Hurtado-Nedelec M; Pilard N; Lebrec D; Valla D; Durand F; de la Grange P; Monteiro RC; Paugam-Burtz C; Lotersztajn S; Moreau R
J Hepatol; 2017 May; 66(5):930-941. PubMed ID: 28040548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
